The company also posted a net loss for the quarter of CA$6.19 million versus a net loss of CA$2.07 million in the third quarter of 2018.
It disclosed a loss per basic and diluted share of CA$0.33, higher than a loss per share of CA$0.14 in the corresponding quarter of the previous year.
During the third quarter, the company produced the first commercial batch of Pura Earth branded derma-cosmetic products; obtained a Health Canada cannabis research license; entered a joint venture with Sigma Analytical Services for the testing of cannabis and cannabis-based products in Colombia; signed an agreement with the University of Guelph to test the effectiveness of its products in various conditions; and added 120,000 square feet of cultivation space.
Don’t miss out on the top cannabis stories of the day. Click here to sign up for our daily insider newsletter.
"We have built tremendous momentum and have connected several international verticals into a unified vertically integrated model in recent months,” CEO Aras Azadian said in a statement. “During this time, we have initiated several revenue streams through our various product lines, which we expect to drive the company's future growth.
Years of hard work and R&D are coming together to result in commercial cannabinoid products at a time when global market demand is increasing, Azadian said.
Avicanna shares were down 5.74% at $1.32 at the time of publication Friday.